Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Dry Eye Disease Clinical Trials

A listing of Dry Eye Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (74) clinical trials

A Multi-Center Randomized Double-Masked Parallel-Group Vehicle-Controlled Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease

Phase

The RENEW Trial: A Multi-Center Randomized Double-Masked Parallel-Group Vehicle-Controlled Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Phase

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.

Phase

Dry Eye Syndrome Description During Cataract Surgery With Multimodal Analysis of the Ocular Surface

Type of study: Descriptive study, interventional research involving the human person at risk and with minimal constraints (type 2), prospective, with longitudinal cohort follow-up, mono-centric. Number of centres: 1; The protocol will take place in the ophthalmology department of the Clermont-Ferrand University Hospital. Study description: The study will follow the ...

Phase N/A

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Redwood Pharma is developing the novel ophthalmic product RP101 containing the known active substance 17-oestradiol-3-phosphate and based upon the drug delivery platform IntelliGel which controls the active substance release. The novel formulation is planned to meet the still unmet medical need of an efficacious treatment against chronic dry eye in ...

Phase

Management of Signs and Symptoms Associated With Dry Eye Disease

A prospective randomized, and controlled study to compare the effectiveness of PROKERA SLIM plus standard of care (SOC) in the PROKERA SLIM Arm to SOC alone in the Control Arm. Subjects presenting with moderate DED defined as corneal fluorescein staining score of 3 points out of 9 will be recruited.

Phase N/A

Assessment of the Mu-Drop System for Serum Eye Drops

Rationale: Serum eye drops (SEDs) are used to treat patients with severe signs and symptoms of dry eyes and other corneal defects. Serum is used in severe ophthalmic cases where conventional treatment and/or eye drops (artificial tears) have insufficient effect. The use of SEDs in dry eye patients usually has ...

Phase N/A

Efficacy and Safety of Hydrolysed Red Ginseng Extract on Dry Eye

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 46 subjects were randomly divided into Hydrolysed Red Ginseng extract 10ml or placebo group. The investigators measured Ocular Surface Disease Index, tear break-up time, Visual analog scale, Schirmer's test, meibomian gland test and Fluorescein staining.

Phase N/A

Clinical Trial to Evaluate the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-2 Study)

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease (DED)

Phase

Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease

The purpose of this study is to evaluate goblet cell degranulation following acute use of the Intranasal Tear Neurostimulator in participants with dry eye.

Phase N/A